Celcuity

Celcuity Long-term Debt

The Long-Term Debt of Celcuity (CELC) as of Nov 8, 2026 is 321.85 M USD. In the previous year, Long-Term Debt was 97.73 M USD — a change of 229.34% (higher).

Long-term Debt

321.85 MUSD

YoY

229.34%

Last updated:

Long-Term Debt of Celcuity is 2025 321.85 M USD. Long-Term Debt of Celcuity was 2024 97.73 M USD. It decreases by 229.34% higher compared to the previous year.

The Celcuity Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2017
0.00 USD
Jan 1, 2018
19,880.00 USD
Jan 1, 2019
14,110.00 USD
Jan 1, 2021
14.63 M USD
Jan 1, 2022
34.98 M USD
Jan 1, 2023
37.04 M USD
Jan 1, 2024
97.73 M USD
Jan 1, 2025
321.85 M USD
The Celcuity Long-term Debt history
YEARLong-term DebtYoY
321.85 MUSD+229.34%
97.73 MUSD+163.87%
37.04 MUSD+5.87%
34.98 MUSD+139.19%
14.63 MUSD+103,556.44%
14,110.00USD-29.02%
19,880.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Long-Term Debt of Celcuity is 321.85 M USD in 2025.

Long-Term Debt of Celcuity changed from 97.73 M USD to 321.85 M USD, representing a 229.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Celcuity since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Celcuity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Celcuity

All Key Metrics — Celcuity